SCHEMBL4982209

SCHEMBL4982209

CC(=O)N(S(C)(=O)=O)S(C)(=O)=O

nearest known ligand 0.32

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.31
CYP3A4 P08684 1/20 0.31
LMNA P02545 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28449489 0.76 KDM4E (0.33) KDM4ECYP3A4CA2
SCHEMBL29202325 0.73 KDM4E (0.31) KDM4ECYP3A4CA2
SCHEMBL136628 0.71
SCHEMBL30640697 0.71 TSHR (0.33)
SCHEMBL585350 0.71 CA1 (0.33) LMNA
SCHEMBL570625 0.70
SCHEMBL14845091 0.69
SCHEMBL14845089 0.69
SCHEMBL14845088 0.69
Dimethyl Sulfone SCHEMBL29098852 0.69 KDM4E (0.43) KDM4ECYP3A4LMNACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3310746-A1 NEW CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL Targent, LLC (US) 2018-04-25 EP claimed
WO-2016205299-A1 NEW CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL TARGENT, LLC (US) 2016-12-22 WO claimed
WO-2024038887-A1 POLYMER COMPOSITION AND SINGLE-LAYER RETARDATION MATERIAL 日産化学株式会社 2024-02-22 WO disclosed
US-20220296725-A1 PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES MERSANA THERAPEUTICS, INC. 2022-09-22 US disclosed
EP-2970330-A1 TETRACYCLIC BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-01-20 EP disclosed
WO-2014139324-A1 TETRACYCLIC BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-09-18 WO disclosed
WO-2008035315-A9 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LAB LTD (IN) 2008-10-23 WO disclosed
EP-1585481-A2 PYRAZOLOPYRIMIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2005-10-19 EP disclosed
WO-2005023783-A1 PROCESS FOR THE MANUFACTURE OF GEFITINIB ASTRAZENECA AB (SE) 2005-03-17 WO disclosed
WO-2004064721-A2 A PYRAZOLOPYRIMIDINE COMPOUND AND A PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2004-08-05 WO disclosed
US-4874834-A FROM AROMATIC DIAMINE AND TETRACARBOXYLIC ACID NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) 1989-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296725-A1 PYRROLOBENZODIAZEPINE ANTIBODY CONJUGATES GABRA4, GABRA1, GABRA2 KDM4E 1256/4885CYP3A4 246/4885LMNA 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.